Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Profarma Distribuidora de Produtos Farmacêuticos S.A. (PFRM3.SA)
Rio De Janeiro, RJ, BR
Established in 1961 and headquartered in Rio de Janeiro, Brazil, Profarma Distribuidora de Produtos Farmacêuticos S.A. is a prominent player in the Brazilian healthcare market, focusing on both the wholesale and retail sales of pharmaceutical and hospital supplies. The company's operations are divided into distinct Distribution and Retail segments. Its comprehensive product offerings include a vast array of pharmaceuticals, such as brand-name drugs, generic alternatives, and over-the-counter medications. Profarma also supplies essential hospital products, including injectable and infusion therapies for specialized medical areas like oncology, endocrinology, rheumatology, infectology, and hematology. Furthermore, it provides specific treatments such as vaccines for conditions like influenza, HPV, meningitis, hepatitis, chickenpox, and dengue, alongside specialized medicines for rare and complex diseases. Beyond pharmaceuticals, the company distributes a wide selection of personal care, beauty, and cosmetic items. This category encompasses shampoos, conditioners, treatment creams, hair dyes, baby products like diapers, soaps, deodorants, oral care essentials, sunscreens, men's grooming products, cosmetics, makeup, and skincare. Profarma also features proprietary lines under the Nº21, GOnutri, and Bem Básico brands, offering exclusive hygiene and beauty products, vitamins, and workshop items. Complementing these, convenience goods such as food products, blood pressure monitors, and scales are also available. The company extends its services to include promotional and logistical support, implementation of marketing campaigns, product recall management, development of bespoke solutions for laboratories, and oversight of clinical procedures. As of December 31, 2019, Profarma's infrastructure boasted eleven strategically located distribution centers across several Brazilian states (Alagoas, Bahia, Espírito Santo, Goiás, Minas Gerais, Paraíba, Paraná, Pernambuco, Rio Grande do Sul, Rio de Janeiro, and São Paulo). Its retail footprint comprised approximately 196 stores operating under the Drogarias Tamoio, Drogasmil, Farmalife, and Rede Rosário banners, situated in the states of Rio de Janeiro, Goiás, Tocantins, Mato Grosso, and Distrito Federal.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.58% | -1.67% | -14.42% | -16.94% | -14.53% | -16.75% | -10.52% | +135.33% | +44.08% | +8.12% | -58.42% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+12.8% ★ Q1'26: +6.0% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+4.3% Q1'26: -115.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+1.3% Q1'26: -1.0% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+3.3% ★ Q1'26: +2.1% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+13.6% ★ Q1'26: +4.9% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×2.41× Q1'26: 3.56× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.47B
est: 3.55B (-2.3%)
|
4.08B
est: 4.07B (+0.3%)
|
4.10B
est: 4.65B (-11.8%)
|
4.27B
est: 4.14B (+3.1%)
|
4.80B
est: 4.23B (+13.5%)
|
5.48B
est: 4.56B (+20.1%)
|
6.41B
est: 4.87B (+31.7%)
|
10.15B
est: 4.07B (+149.4%)
|
11.45B
est: 4.07B (+181.3%)
|
4.65B
4.65B – 4.65B
+14.2% YoY
|
4.14B
4.14B – 4.14B
-10.9% YoY
|
4.23B
4.23B – 4.23B
+2.2% YoY
|
4.56B
4.56B – 4.56B
+7.8% YoY
|
4.87B
4.87B – 4.87B
+6.7% YoY
|
| EBITDA |
102.11M
est: 140.22M (-27.2%)
|
125.12M
est: 160.97M (-22.3%)
|
41.19M
est: 183.82M (-77.6%)
|
70.25M
est: 163.73M (-57.1%)
|
206.76M
est: 167.33M (+23.6%)
|
182.99M
est: 180.42M (+1.4%)
|
226.44M
est: 192.52M (+17.6%)
|
401.46M
est: 250.72M (+60.1%)
|
581.79M
est: 250.72M (+132.0%)
|
286.32M
286.32M – 286.32M
+14.2% YoY
|
255.03M
255.03M – 255.03M
-10.9% YoY
|
260.64M
260.64M – 260.64M
+2.2% YoY
|
281.02M
281.02M – 281.02M
+7.8% YoY
|
299.87M
299.87M – 299.87M
+6.7% YoY
|
| EBIT |
85.83M
est: 76.56M (+12.1%)
|
105.61M
est: 87.89M (+20.2%)
|
9.72M
est: 100.37M (-90.3%)
|
36.52M
est: 89.40M (-59.2%)
|
111.46M
est: 91.37M (+22.0%)
|
81.05M
est: 98.51M (-17.7%)
|
100.56M
est: 105.12M (-4.3%)
|
231.94M
est: 190.03M (+22.1%)
|
381.63M
est: 190.03M (+100.8%)
|
217.01M
217.01M – 217.01M
+14.2% YoY
|
193.30M
193.30M – 193.30M
-10.9% YoY
|
197.54M
197.54M – 197.54M
+2.2% YoY
|
212.99M
212.99M – 212.99M
+7.8% YoY
|
227.28M
227.28M – 227.28M
+6.7% YoY
|
| Net Income |
-21.18M
est: -42.41M (+50.1%)
|
-48.96M
est: 13.95M (-450.9%)
|
-112.72M
est: -65.69M (-71.6%)
|
-9.73M
est: -6.13M (-58.8%)
|
11.98M
est: 29.43M (-59.3%)
|
52.33M
est: 51.50M (+1.6%)
|
78.19M
est: 66.21M (+18.1%)
|
114.58M
est: 13.95M (+721.2%)
|
118.90M
est: 13.95M (+752.1%)
|
-65.69M
-65.69M – -65.69M
-570.8% YoY
|
-6.13M
-6.13M – -6.13M
+90.7% YoY
|
29.43M
29.43M – 29.43M
+580.0% YoY
|
51.50M
51.50M – 51.50M
+75.0% YoY
|
66.21M
66.21M – 66.21M
+28.6% YoY
|
| SGA |
357.57M
est: 311.89M (+14.6%)
|
381.90M
est: 358.03M (+6.7%)
|
520.82M
est: 408.86M (+27.4%)
|
479.01M
est: 364.19M (+31.5%)
|
420.49M
est: 372.19M (+13.0%)
|
415.12M
est: 401.30M (+3.4%)
|
666.59M
est: 428.21M (+55.7%)
|
1.27B
est: 393.70M (+222.2%)
|
1.37B
est: 393.70M (+247.7%)
|
449.60M
449.60M – 449.60M
+14.2% YoY
|
400.47M
400.47M – 400.47M
-10.9% YoY
|
409.27M
409.27M – 409.27M
+2.2% YoY
|
441.28M
441.28M – 441.28M
+7.8% YoY
|
470.87M
470.87M – 470.87M
+6.7% YoY
|
| EPS |
-0.48
est: -0.35 (-38.8%)
|
-0.82
est: 0.11 (-820.6%)
|
-1.49
est: -0.54 (-178.1%)
|
-0.08
est: -0.05 (-66.2%)
|
0.10
est: 0.24 (-59.3%)
|
0.43
est: 0.42 (+2.4%)
|
0.64
est: 0.54 (+18.5%)
|
0.93
est: 0.11 (+717.2%)
|
0.97
est: 0.11 (+752.4%)
|
-0.54
-0.54 – -0.54
-570.8% YoY
|
-0.05
-0.05 – -0.05
+90.7% YoY
|
0.24
0.24 – 0.24
+580.0% YoY
|
0.42
0.42 – 0.42
+75.0% YoY
|
0.54
0.54 – 0.54
+28.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 104.0K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 49.7K | 0.28% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 133.97 | 0.56% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David da Silva Castro | Corporate Vice President & Member of Board of Executive Officer | — | male |
| Maximiliano Guimarães Fischer | Vice President of Finance & Investor Relations and Member of Board of Executive Officer | — | male |
| Sammy Birmarcker | Vice President of Board, Chief Executive Officer, President & Member of Board of Executive Officers | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PFRM3.SA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
